Outcomes and complications after splenectomy for hematologic disorders.
Am J Surg
; 204(6): 1014-9; discussion 1019-20, 2012 Dec.
Article
en En
| MEDLINE
| ID: mdl-23116640
ABSTRACT
BACKGROUND:
Splenectomy is generally a second-line therapy in patients with immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AHA) refractory to medical therapy. Our objective was to evaluate outcomes after splenectomy for these disorders.METHODS:
A retrospective review of the medical records of patients who underwent splenectomy for ITP or AHA from January 1, 1996, to December 31, 2010 was completed.RESULTS:
Sixty patients met the study criteria 45 with ITP and 15 with AHA. The mean age was 49.4 ± 21.7 years; 63% were women. Initially, 91% and 93% of ITP and AHA patients experienced a complete response (P = .999); however, 17% of ITP and 29% of AHA patients relapsed (P = .443). Sixty-four percent of patients responded after relapse for a complete response rate of 85% (82% in ITP and 93% in AHA, P = .427). Thirty-day and long-term complication rates were 10% and 5%, respectively. There were no splenectomy-related 30-day mortalities.CONCLUSIONS:
Splenectomy for ITP and AHA resulted in favorable response rates with low morbidity and is an effective adjunct in the management course of patients failing to achieve or sustain responses with medical therapy.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Esplenectomía
/
Púrpura Trombocitopénica Idiopática
/
Anemia Hemolítica Autoinmune
Tipo de estudio:
Evaluation_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Surg
Año:
2012
Tipo del documento:
Article
País de afiliación:
Estados Unidos